Rising APAC Device MnA Demonstrates The Need For Regulatory Strategy
This article was originally published in SRA
Executive Summary
The number of M&A deals across Asia Pacific is increasing rapidly. But demonstration of product regulatory compliance is often not transferrable between APAC countries. How do you overcome this and other regulatory hurdles during your M&A deal-making? In this article, Ee Von Teo and Daniel Tan, together with their colleagues*, explain how to manage this dynamic new market opportunity. They also give a breakdown of the different medical device regulatory regimes in APAC and the transferability of registrations and licences by individual countries.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.